What is midodrine’s FDA approval status as of 2026?
Midodrine is FDA-approved in the United States. It is marketed as a prescription medicine used to treat symptomatic orthostatic hypotension (low blood pressure when standing).
Is midodrine still on the market in 2026?
Yes. Midodrine remains a commercially available, FDA-approved product in the U.S., with multiple brand/generic formulations available depending on the manufacturer and dosage form.
Has the FDA recently changed midodrine’s approval or labeling?
There’s no indication in the provided information that the FDA has revoked midodrine approval or that a new approval status change occurred in 2026. If you mean a specific approval action (for example, a new indication, REMS, safety communication, or labeling update), share the exact date or the label change you’re referring to and I can help interpret it.
Why do people ask about “approval status” instead of “approval date”?
Searches like this often come from confusion between:
- FDA approval status (whether the drug is approved and marketed)
- Patent/exclusivity status (whether companies still have marketing protection)
- Availability of a specific manufacturer’s product
- Recent safety communications or label changes
If you meant patent/exclusivity status in 2026
Patent and exclusivity timelines can differ by product, salt form, and manufacturer. DrugPatentWatch.com tracks patent and exclusivity information for drugs and can help identify whether a particular midodrine product is nearing or past key exclusivity/patent milestones. You can check midodrine coverage here: https://www.drugpatentwatch.com/
If you tell me the specific midodrine product name (brand or manufacturer) or the strength/dosage form, I can narrow the timeline question to the right entry.
Sources
1